ClinicalTrials.gg
RecruitingNCT05015660Updated Mar 11, 2026

Conduction System Pacing With Left Bundle Branch Pacing as Compared to Standard Right Ventricular Pacing

An interventional study of Left bundle branch pacing lead and Right ventricular active fixation lead in Pacemaker DDD and Heart Block, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

High burden right ventricular (RV) pacing has been shown to increase cardiovascular mortality, incidence of heart failure (HF), worsen left ventricular (LV) function and accelerate the development of atrial fibrillation (AF). High percentage ventricular pacing and wider paced QRS in the setting of normal baseline LV ejection fractions have consistently been shown to be independent risk factors for pacing-induced cardiomyopathy. Left bundle branch pacing (LBBP) has emerged as a potential alternative pacing mechanism that may avoid LV dyssynchrony and pacing-induced LV dysfunction by mimicking native electrical conduction.

Read the detailed description

We hypothesize that in patients with high degree AV block with anticipated ventricular pacing >90%, and an EF >35% patients undergoing LBBP will demonstrate a significantly lower number of the primary composite endpoint of cardiovascular death, heart failure events, and change in LVESVi as compared to standard RV pacing. Echos will be performed at baseline, 12, 24, and 36 months. NTproBNPs are performed at baseline and follow-up. There will be a core echo lab, and blinded adjudication of ECGs and events.

02

Conditions studied

  • Pacemaker DDD
  • Heart Block

Browse trials for

Keywords

  • left bundle branch pacing
03

In context

Heart Block

39 studies on the registry are indexed under Heart Block; 12 are open to participants now.

This study's planned enrollment of 1,300 is above the median of 104 across 24 interventional studies indexed under Heart Block.

Browse Heart Block studies →

Lead sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre is the lead sponsor of 422 studies on the registry; 106 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Patients with an of >35%
  3. Patients with an indication for ventricular pacing and high-degree atrioventricular block where the degree of anticipated RV pacing is >90% including:

    1. Third degree AV block
    2. Symptomatic or asymptomatic second-degree AV block
    3. First degree AV block ≥ 280ms with a narrow QRS, or ≥ 240ms with an intraventricular delay (QRS duration ≥120ms)
  4. Echocardiogram within the last 3 months, with ability to have DICOM images

Exclusion criteria

Exclusion Criteria:

  1. Indication for an implantable cardioverter defibrillator
  2. Presence of a mechanical tricuspid valve
  3. Any prior attempt at implantation of an ICD, CRT, HBP, or LBBP
  4. Lack of capacity to consent
  5. Other serious medical condition with of \<2 years
  6. Pregnancy
  7. Patients in whom the conduction system abnormality is expected to be transient or recover over time
  8. Patients with permanent atrial fibrillation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,300 participants (estimated)

Study arms

  • Experimental
    left bundle branch pacing

    Device: Left bundle branch pacing lead

  • Active comparator
    Right ventricular pacing

    Device: Right ventricular active fixation lead

Interventions

  • DeviceLeft bundle branch pacing lead

    Implantation of a left bundle branch pacing lead via sheath, to perform selective or non-selective pacing

  • DeviceRight ventricular active fixation lead

    Active fixation lead (standard)

06

What researchers measure

Primary outcomes

  1. Time to cardiovascular death

    Clinical

    Time frame: 36 months

  2. Time to first heart failure event

    Defined as: (i) Emergency department (ED) visits or hospitalization for HF (requiring signs and symptoms consistent with congestive heart failure (CHF) that is responsive to oral or parenteral medications); (ii) intensification of therapy (intravenous diuretic therapy on an outpatient basis); or (iii) indication for device upgrade to CRT due to deteriorating LV function defined as an absolute decline in LVEF ≥ 10% from baseline and an LVEF ≤ 40%

    Time frame: 36 months

  3. Worsening LV end systolic volume index by 2 years

    Defined as a 15% increase from baseline each year up to the two-year echo

    Time frame: 24 months

Secondary outcomes

  1. Cardiovascular mortality

    CV-related

    Time frame: 24 months

  2. New visit for Heart Failure

    Heart failure visit is defined as: i) Emergency department visit or hospitalization for signs and symptoms of HF that is responsive to oral or intravenous diuretics ii) intensification of therapy defined as outpatient intravenous diuretic therapy, and iii) device upgrade to cardiac resynchronization therapy.

    Time frame: 24 months

  3. Total mortality

    Total mortality

    Time frame: 24 months

  4. Change in left ventricular ejection fraction

    Echo parameter, change from baseline to 24 months

    Time frame: 24 months

  5. Change in NTproBNP level

    From baseline to 24 months

    Time frame: 24 months

  6. Atrial fibrillation progression

    Atrial fibrillation burden as noted on pacemaker

    Time frame: 24 months

  7. Development of new tricuspid regurgitation

    More than mild TR from baseline

    Time frame: 24 months

  8. Presence of Mitral regurgitation

    Progression/Development from baseline

    Time frame: 24 months

  9. Change in Lead parameter

    stability of impedance, sensing, thresholds

    Time frame: 24 months

  10. Quality of Life Improvement

    Health related quality of life score: Short Form 12

    Time frame: Evaluated at 1, 12, and 24 months, measure as compared to baseline

  11. Safety of procedure and long-term safety

    Procedural and long-term safety of left bundle pacing

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2022 (actual). Primary completion is estimated for Dec 2026, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2021
First posted
Aug 20, 2021
StartActual
Sep 1, 2022
Primary completionEst.
Dec 1, 2026
CompletionEst.
Jan 1, 2030
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05015660
Collaborators
Heart and Stroke Foundation of Canada, Canadian Institutes of Health Research (CIHR)
Responsible party
Jacqueline Joza (Cardiac electrophysiologist, McGill University Health Centre/Research Institute of the McGill University Health Centre) — Principal investigator
First posted
Aug 20, 2021
Start date
Sep 1, 2022
Primary completion
Dec 1, 2026 (estimated)
Completion
Jan 1, 2030 (estimated)
Last update
Mar 11, 2026

Study contacts

Jacqueline Joza, MD MSc
Contact
jacqueline.joza@gmail.com
514-934-1934 ext. 43158
Fiorella Rafti, PhD
Contact
fiorella.rafti@mail.mcgill.ca
514-934-1934

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion